Centessa Pharmaceuticals plc CEO Sells 928,950.00 in Stock
CNTA Stock | USD 17.60 0.30 1.73% |
About 58% of all Centessa Pharmaceuticals' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Centessa Pharmaceuticals PLC suggests that some traders are interested. The current market sentiment, together with Centessa Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Centessa Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Centessa |
Centessa Pharmaceuticals plc CEO Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of 16.89, for a total transaction of 928,950.00. Following the sale, the chief executive officer now directly owns 575,661 shares of the
Read at thelincolnianonline.com
Centessa Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Centessa Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Centessa Pharmaceuticals Fundamental Analysis
We analyze Centessa Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Centessa Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Centessa Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Outstanding
Shares Outstanding Comparative Analysis
Centessa Pharmaceuticals is currently under evaluation in shares outstanding category among its peers. Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Centessa Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Centessa Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Centessa Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Centessa Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Centessa Pharmaceuticals Related Equities
IPSC | Century Therapeutics | 20.74 | ||||
CCCC | C4 Therapeutics | 8.59 | ||||
GLUE | Monte Rosa | 5.93 | ||||
ERAS | Erasca | 5.04 | ||||
MLYS | Mineralys Therapeutics, | 4.71 | ||||
STRO | Sutro Biopharma | 3.46 | ||||
IRON | Disc Medicine | 3.03 | ||||
CGEM | Cullinan Oncology | 2.51 | ||||
TARS | Tarsus Pharmaceuticals | 2.38 | ||||
TRDA | Entrada Therapeutics | 2.37 | ||||
OPT | Opthea | 1.83 | ||||
NAMSW | NewAmsterdam Pharma | 1.68 | ||||
CRNX | Crinetics Pharmaceuticals | 1.59 | ||||
GNFT | Genfit | 0.95 | ||||
HLVX | Hillevax | 0.52 | ||||
NUVL | Nuvalent | 0.48 | ||||
EWTX | Edgewise Therapeutics | 0.37 | ||||
LRMR | Larimar Therapeutics | 0.00 | ||||
DSGN | Design Therapeutics | 2.93 |
Complementary Tools for Centessa Stock analysis
When running Centessa Pharmaceuticals' price analysis, check to measure Centessa Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Centessa Pharmaceuticals is operating at the current time. Most of Centessa Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Centessa Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Centessa Pharmaceuticals' price. Additionally, you may evaluate how the addition of Centessa Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |